Current Report Filing (8-k)
March 04 2019 - 5:03PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): March 4, 2019
SYNTHETIC
BIOLOGICS, INC.
(Exact name of registrant as specified in
its charter)
Nevada
|
|
001-12584
|
|
13-3808303
|
(State or other jurisdiction of incorporation)
|
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
9605 Medical Center Drive, Suite 270
Rockville, MD 20850
(Address of principal executive offices
and zip code)
Registrant’s telephone number, including
area code: (301) 417-4364
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate
by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 8.01. Other Events.
Synthetic Biologics, Inc. (the “Company”)
will be making corporate presentations over the next several weeks, including a presentation at the 2019 BIO Asia Conference on
Wednesday, March 6, 2019, in Tokyo, Japan. In connection with the presentations, the Company intends to discuss the slide presentation
attached as Exhibit 99.1 hereto, which is incorporated herein by reference.
The slide presentation attached as Exhibit
99.1 to this Current Report on Form 8-K includes “safe harbor” language pursuant to the Private Securities Litigation
Reform Act of 1995, as amended, indicating that certain statements contained in the slide presentation or in the press release
are “forward-looking” rather than historical.
The Company undertakes no duty or obligation
to update or revise information included in this Current Report on Form 8-K or Exhibit 99.1 hereto.
Item 9.01. Financial Statements and Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 4, 2019
|
SYNTHETIC BIOLOGICS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Steven A. Shallcross
|
|
Name:
|
Steven A. Shallcross
|
|
Title:
|
Chief Executive Officer and
Chief Financial Officer
|
EXHIBIT INDEX
Synthetic Biologics (AMEX:SYN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Synthetic Biologics (AMEX:SYN)
Historical Stock Chart
From Sep 2023 to Sep 2024